In the latest trading session, Novo Nordisk (NVO) closed at $80.57, marking a -0.57% move from the previous day.

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

Ameritas Advisory Services LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 453.3% during ...

Following Adidas' lead, Puma (OTC: PMMAF )'s shares also rose by 2.5%. Germany's benchmark index outperformed its regional counterparts by adding 0.9%, reaching a record high.

(Reuters) - European stocks extended their recent run of gains on Wednesday, with strong holiday-quarter performance from ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of ...

CFRA analyst Wan Nurhayati revised the price target for Novo Nordisk (NYSE:NVO) shares, reducing it to $90 from the previous target of $122. Despite the price target cut, the analyst retained a Hold ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...